• Oligo (dT) 25 Beads for Immune-Cell RNA Assays

  2026-09-20

  Oligo (dT) 25 Beads provide selective polyA tail mRNA capture for rigorous eukaryotic immune-cell RNA workflows. This guide explains how their use can support, but should not be confused with, single-cell studies of immune rejuvenation in Alzheimer’s disease models.

• LNP-mRNA Fibroblasts for Intervertebral Disc Repair

  2026-09-19

  The reference study develops fibroblasts engineered with lipid nanoparticle-delivered mRNA encoding a TNF-α-neutralizing antibody, combining cell-based delivery with local cytokine modulation. In inflammatory cell experiments and a rat intervertebral disc degeneration model, the engineered cells protected fibroblast function, improved extracellular matrix-related outcomes, and produced greater disc-height preservation than unmodified fibroblasts.

• PF-573228: FAK Inhibitor Evidence & Workflow

  2026-09-18

  PF-573228 is an ATP-competitive FAK inhibitor with a reported biochemical IC50 of 4 nM. Evidence supports its use for dissecting FAK phosphorylation, cancer cell migration, endothelial responses, and FAK/MAPK/ERK signaling in experimental models.

• Tin Mesoporphyrin IX: HO Inhibition Guide

  2026-09-18

  Tin Mesoporphyrin IX (chloride) is a competitive heme oxygenase inhibitor with a reported in vitro Ki of 14 nM against rat splenic microsomal heme oxygenase. Its strongest research value is as a mechanistic tool for heme catabolism, metabolic disease research, and carefully controlled HO-linked redox studies rather than as a clinical or established antiviral treatment.

• RapaLink-1: Designing Better mTOR Assays

  2026-09-17

  RapaLink-1 is a third-generation mTOR inhibitor that enables more discriminating studies of mTORC1 inhibition, resistant signaling, and phenotype. This article develops an assay-design framework linking its bivalent pharmacology to insights from reversible embryonic dormancy models.

• Caged Bioluminescent Probe for Immunoproteasome

  2026-09-17

  Loy and Trader describe a cleavable, bioluminescent activity-based probe designed to report immunoproteasome activity, with emphasis on the β5i-containing isoform. The synthesis and plate-reader workflow offers a practical route for studying immunoproteasome function in cellular systems and tissue-mimicking conditions, while the authors identify in vivo translation as an important next step.

• NBC19: Linking Inflammasome Assays to CAML Biology

  2026-09-16

  NBC19, a potent NLRP3 inflammasome inhibitor, offers a precise way to test how inflammatory signaling may intersect with circulating cancer-associated macrophage-like cells. This article translates CAML phenotyping insights into better assay design while clearly separating established evidence from testable hypotheses.

• Tyrothricin: Applied Antimicrobial Workflows

  2026-09-16

  Tyrothricin is a peptide antibiotic mixture suited to rapid, mechanism-focused studies of microbial membrane injury across bacteria and selected nonbacterial models. This guide translates the product’s membrane-disruption profile and a redox-biology reference study into practical assay design, controls, and troubleshooting steps.

• ER-Targeting Peptide Self-Assembly in Cancer Cells

  2026-09-15

  The reference study develops an alkaline-phosphatase-triggered peptide that self-assembles at the endoplasmic reticulum through a p-toluenesulfonamide targeting group. This design selectively increases ER stress and cancer-cell death while reducing the concentration dependence of earlier intracellular enzyme-instructed self-assembly strategies.

• CGP 55845 Hydrochloride in GABAB Assays

  2026-09-14

  Use CGP 55845 hydrochloride as a receptor-level control when separating GABAB signaling from astrocytic GAT-3 effects in dentate gyrus experiments. This practical guide connects antagonist pharmacology with whole-cell recording, calcium imaging, optogenetics, and neurotransmitter release modulation while emphasizing in vitro interpretation limits.

• Moxifloxacin: From Gyrase Traps to Toxicity Models

  2026-09-14

  Moxifloxacin is a fluoroquinolone antibiotic that connects bacterial DNA-gyrase pharmacology with cellular and metabolic toxicity research. This guide presents a target-engagement framework for selecting assays, interpreting retinal-cell findings, and controlling compound handling.

• Dehydroepiandrosterone (DHEA) Research Workflows

  2026-09-13

  Dehydroepiandrosterone (DHEA) supports two distinct research strategies: endocrine challenge modeling in ovarian biology and concentration-controlled studies of neural survival. This practical guide connects formulation, assay design, and troubleshooting with the mitochondrial steroidogenesis findings reported in a recent PCOS study.

• Prednisone as a Translational Immunology Benchmark

  2026-09-12

  Prednisone offers translational researchers a defined synthetic corticosteroid benchmark for studying lymphocyte cell-cycle control, IL-2 signaling, apoptosis, formulation variables, and the limits of connecting immune assays with neurodegeneration models.

• BV6: Reframing IAP Antagonism for Translation

  2026-09-11

  BV6 is a Smac-mimetic IAP antagonist that provides a mechanistically tractable way to study apoptosis, treatment sensitization, and disease-model biology. This thought-leadership analysis connects IAP-dependent survival signaling with RIPK3–MLKL pathway resolution, offering translational researchers a strategy for stronger experimental design without overstating preclinical evidence.

• Cefepime (BMY-28142) in CNS Infection Models

  2026-09-11

  Explore how Cefepime (BMY-28142) can support central nervous system infection research through mechanism-informed antibacterial, barrier-transport, and neurotoxicity assays. This guide translates cephalosporin PK/PD principles into practical experimental decisions without conflating cefepime with newer comparator antibiotics.

8537 records 1/570 page Next 12345 下5页 Last page